145 related articles for article (PubMed ID: 32238495)
21. Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology.
Tan N; Shen L; Khoshnoodi P; Alcalá HE; Yu W; Hsu W; Reiter RE; Lu DY; Raman SS
J Urol; 2018 May; 199(5):1218-1223. PubMed ID: 29128577
[TBL] [Abstract][Full Text] [Related]
22. 11C- or 18F-Choline PET/CT for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer.
Mapelli P; Incerti E; Ceci F; Castellucci P; Fanti S; Picchio M
J Nucl Med; 2016 Oct; 57(Suppl 3):43S-48S. PubMed ID: 27694171
[TBL] [Abstract][Full Text] [Related]
23. A Statewide Intervention Improves Appropriate Imaging in Localized Prostate Cancer.
Hurley P; Dhir A; Gao Y; Drabik B; Lim K; Curry J; Womble PR; Linsell SM; Brachulis A; Sexton DW; Ghani KR; Denton BT; Miller DC; Montie JE;
J Urol; 2017 May; 197(5):1222-1228. PubMed ID: 27889418
[TBL] [Abstract][Full Text] [Related]
24. Prostate cancer imaging: what surgeons, radiation oncologists, and medical oncologists want to know.
Tabatabaei S; Saylor PJ; Coen J; Dahl DM
AJR Am J Roentgenol; 2011 Jun; 196(6):1263-6. PubMed ID: 21606287
[TBL] [Abstract][Full Text] [Related]
25. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
26. Prostate MR Imaging for Posttreatment Evaluation and Recurrence.
Gaur S; Turkbey B
Urol Clin North Am; 2018 Aug; 45(3):467-479. PubMed ID: 30031466
[TBL] [Abstract][Full Text] [Related]
27. [The role of PSMA PET-CT in patients with metastatic prostate cancer].
von Hardenberg J; Büsing KA; Nuhn P; Ritter M
Urologe A; 2017 Nov; 56(11):1410-1416. PubMed ID: 28980045
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of Posttreatment Follow-Up of Patients With Prostate Cancer Relative to the American College of Radiology's Appropriateness Criteria.
McDonald JS; Carter RE; Karnes RJ; Port JD; Kawashima A; Carlson SK; Bender CE
AJR Am J Roentgenol; 2015 Nov; 205(5):1008-15. PubMed ID: 26496548
[TBL] [Abstract][Full Text] [Related]
29. Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the Cart.
Vapiwala N; Hofman MS; Murphy DG; Williams S; Sweeney C
J Clin Oncol; 2019 Apr; 37(10):765-769. PubMed ID: 30794477
[No Abstract] [Full Text] [Related]
30. Contribution of Radiology to Staging of Prostate Cancer.
Woo S; Ghafoor S; Vargas HA
Semin Nucl Med; 2019 Jul; 49(4):294-301. PubMed ID: 31227052
[TBL] [Abstract][Full Text] [Related]
31. Impact of functional imaging in prostate cancer: a clinical point of view.
Nicolotti DG; Finessi M; Guarneri A; Pilati E; Giunta F; Deandreis D
Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):1-6. PubMed ID: 30644307
[No Abstract] [Full Text] [Related]
32. [PSMA-based theranostics for prostate cancer : From imaging to treatment].
Ilhan H; la Fougère C; Krause BJ
Urologe A; 2020 May; 59(5):617-625. PubMed ID: 32377764
[TBL] [Abstract][Full Text] [Related]
33. Advances in prostate cancer imaging.
Tangel MR; Rastinehad AR
F1000Res; 2018; 7():. PubMed ID: 30467517
[TBL] [Abstract][Full Text] [Related]
34. [Diagnostic relevance of choline-PET / CT in patients with prostate cancer].
Zengerling F; Schrader AJ; Schrader M; Jentzmik F
Aktuelle Urol; 2012 Jan; 43(1):49-54. PubMed ID: 21769763
[TBL] [Abstract][Full Text] [Related]
35. The future of molecular and functional imaging in prostate cancer.
Renard-Penna R; Gauthé M
Arch Esp Urol; 2019 Mar; 72(2):150-156. PubMed ID: 30855016
[TBL] [Abstract][Full Text] [Related]
36. Prostate shapes on pre-treatment MRI between prostate cancer patients who do and do not undergo biochemical recurrence are different: Preliminary Findings.
Ghose S; Shiradkar R; Rusu M; Mitra J; Thawani R; Feldman M; Gupta AC; Purysko AS; Ponsky L; Madabhushi A
Sci Rep; 2017 Nov; 7(1):15829. PubMed ID: 29158516
[TBL] [Abstract][Full Text] [Related]
37. Patterns of failure after primary local therapy for prostate cancer and rationale for secondary therapy.
Grossfeld GD; Li YP; P Lubeck DP; Carroll PR
Urology; 2002 Sep; 60(3 Suppl 1):57-62; discussion 62-3. PubMed ID: 12231051
[TBL] [Abstract][Full Text] [Related]
38. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT.
Eiber M; Herrmann K; Calais J; Hadaschik B; Giesel FL; Hartenbach M; Hope T; Reiter R; Maurer T; Weber WA; Fendler WP
J Nucl Med; 2018 Mar; 59(3):469-478. PubMed ID: 29123012
[TBL] [Abstract][Full Text] [Related]
39. ACR Appropriateness Criteria
; Froemming AT; Verma S; Eberhardt SC; Oto A; Alexander LF; Allen BC; Coakley FV; Davis BJ; Fulgham PF; Hosseinzadeh K; Porter C; Sahni VA; Schuster DM; Showalter TN; Venkatesan AM; Wang CL; Remer EM
J Am Coll Radiol; 2018 May; 15(5S):S132-S149. PubMed ID: 29724417
[TBL] [Abstract][Full Text] [Related]
40. State-of-the-art imaging techniques in the management of preoperative staging and re-staging of prostate cancer.
Schiavina R; Chessa F; Borghesi M; Gaudiano C; Bianchi L; Corcioni B; Castellucci P; Ceci F; Ceravolo I; Barchetti G; Del Monte M; Campa R; Catalano C; Panebianco V; Nanni C; Fanti S; Minervini A; Porreca A; Brunocilla E
Int J Urol; 2019 Jan; 26(1):18-30. PubMed ID: 30238516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
